Description
COATS® (an acronym for Colloidal Oatmeal System) is a patented and unique nitrile glove technology. COATS® utilises the powerful benefits of all-natural oats, an FDA-recognised skin protectant, as a coating that forms a natural, moisturising barrier between the glove and skin. This acts as a preventative measure against skin irritation, and eliminates uncomfortable and irritating conditions experienced when wearing normal gloves. Users who suffer from dry and itchy skin due to frequent hand washing and glove usage can now rely on COATS® to soothe and nurture the skin, and protect their hands while they work.
| REORDER CODE | SIZE |
|---|---|
| CTS38XS | X-Small |
| CTS38SS | Small |
| CTS38MM | Medium |
| CTS38LL | Large |
| CTS38XL | X-Large |
| GLOVE PROPERTIES | MEASUREMENT (MM) |
|---|---|
| Length | ≥230 |
| Thickness at Palm (centre of Palm) | 0.07 ± 0.02 |
| Thickness at Finger (13mm ± 3mm from tip) | 0.09 ± 0.02 |
| MANUFACTURING ACCREDITATIONS | |
|---|---|
| Accreditations | ISO 9001 ISO 13485 EN ISO 13485 |
| CHEMOTHERAPY DRUGS AND CONCENTRATION (TESTED FOR RESISTANCE TO PERMEATION BY CHEMOTHERAPY DRUGS AS PER ASTM D6978-05, TEST REPORT PN 134889A) |
MINIMUM BREAKTHROUGH DETECTION TIME (MINUTES) |
|---|---|
| Carmustine (BCNU), 3.3mg/ml (3,300ppm) | 21.9 |
| Cisplatin, 1.0mg/ml (1,000ppm) | >240 |
| Cyclophosphamide (Cytoxan), 20.0mg/ml (20,000ppm) | >240 |
| Dacarbazine (DTIC), 10.0mg/ml (10,000ppm) | >240 |
| Doxorubicin Hydrochloride, 2.0mg/ml (2,000ppm) | >240 |
| Etoposide (Toposar), 20.0mg/ml (20,000ppm) | >240 |
| Fluorouracil, 50.0mg/ml (50,000ppm) | >240 |
| Methotrexate, 25.0mg/ml (25,000ppm) | >240 |
| Mitomycin C, 0.5mg/ml (500ppm) | >240 |
| Paclitaxel (Taxol), 6.0mg/ml (6,000ppm) | >240 |
| Thiotepa, 10.0mg/ml (10,000ppm) | 36.0 |
| Vincristine Sulfate, 1.0mg/ml (1,000ppm) | >240 |
| WARNING: Carmustine and Thiotepa, at the tested concentration, degraded a COATS® nitrile glove at 21.9 minutes and 36.0 minutes respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such a decision. | |